Yang Yu

Objective: To investigate the effect of combined detection of serum carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), cancer antigen 125 (CA125), and neuron-specific enolase (NSE) in patients with lung cancer by fluorescence flow cytometry. Methods: From August 2019 to July 2022, 200 patients with lung cancer diagnosed by pathology in our hospital were retrospectively analyzed. 2 mL venous blood was collected in a fasting state and centrifuged to separate the serum (containing human chorionic gonadotropin antibody [anti-hCG antibody], hepatitis B surface antibody [anti-HBs antibody], and CEA). Results: The sensitivities of CEA and CYFRA21-1 detected via enzyme-linked immunosorbent assay (ELISA) were 100%, and the detection limits were 0.5 ng/mL and 0.1 ng/mL, respectively; the sensitivities of CA125 and NSE detected via flow cytometry were 100%, and the detection limits were 10 U/mL and 2 ng/mL, respectively. Compared with ELISA, the sensitivities of CA125 and NSE detected via flow cytometry were higher. When the concentration of CEA was 10–40 ng/mL, the sensitivities of the three markers CYFRA21-1, CA125, and NSE showed no significant changes (P > 0.05); when the concentration of CEA was 40–80 ng/mL, the sensitivity of CEA significantly decreased (P < 0.01), but the sensitivities of the three markers CYFRA21-1, CA125, and NSE showed no significant changes (P > 0.05); when the concentration of CEA was 80–200 ng/mL, the sensitivities of all four markers showed no significant changes (P > 0.05). Conclusion: Compared with the double-antibody sandwich ELISA, fluorescence flow cytometry has certain advantages, including high sensitivity, good precision, short detection time, low sample usage, and low medical cost; thus, it is worthy of clinical promotion.

TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis

We report a 28-year-old woman who presented with a 6-year history of milk-like discharge from both of her nipples and was diagnosed with prolactinoma based on computed tomography (CT) findings and serum prolactin level. Further breast examination revealed a mass located in the upper outer region of the left breast. She underwent subtotal pituitary tumor resection. Thereafter, modified radical mastectomy was performed for left breast cancer. Twelve years after treatment, prolactinoma recurrence was detected, and bromocriptine therapy was administered. No recurrence of breast cancer was discovered. Based on this case report, we stress the importance of prolactin levels due to their possible biologic effects on breast cancer induction or growth.

562 Background: In our previous study, goserelin has been reported downregulating the estradiol level, breast density and endometrial thickness in Chinese pre-/peri-menopausal hormone positive (HR+) breast cancer. Here, the prognositic results of this study will be reported: disease-free survival (DFS) and overall survival (OS) of goserelin plus tamoxifen (TAM) versus TAM alone in pre-/peri-menopausal HR+ early-stage breast cancer in China (NCT00827307). Methods: Pre-/peri-menopausal patients with HR+ early-stage breast cancer (after finishing surgery, chemotherapy, radiotherapy if applicable) were randomized to receive either goserelin 3.6mg ih. every 28 days for 1.5 years plus TAM 10 mg po. twice a day for 5 years (Group A) or TAM alone for 5 years (Group B) as adjuvant endocrine therapy. The patients also were classified according to recurrence-risk grade for stratified analysis. The DFS and OS in total patients and in stratified risk grade subgroups were analyzed. Results: From 22 June 2008 to 31 December 2009, 110 eligible patients were recruited. The medium follow-up time is 72 months. Because of 19 cases dropped out, there were 47 patients of group A and 44 patients of group B included in for final analysis. Patients in group A had better DFS and OS than those in group B although not statistically significant due to small sample size (DFS: HR = 0.452, P = 0.261, OS: HR = 0.301, P = 0.299). In high-risk (1~4 LN+ and HER2+/ ≥ 4 LN+) subgroup, there were no patients with recurrent/metastasis (0/10) in group A while three patients with recurrent/metastasis (3/8) in group B, goserelin combined with TAM has better DFS than TAM alone (Log-rank test, χ²= 4.324, P = 0.038). In total patients, COX proportional hazard regression model (forward conditional method) showed that the number of LN+ significantly impacts the DFS (P = 0.011). Meanwhile, both the age and the tumor size have significant impacts on OS (P = 0.028 and P = 0.030, respectively). Conclusions: Goserelin combined with TAM was suggested to improve DFS in HR+ pre-/peri-menopausal breast cancer with high-recurrence risk grade. Clinical trial information: NCT00827307.

The influence of high peritonitis rate (HPR) on clinical outcomes of continuous ambulatory peritoneal dialysis (CAPD) patients has been far less studied in the Chinese population than in those of the USA, Australia and Europe. Furthermore, concerning the peritonitis risk, most studies primarily examined the risk of developing the first peritonitis episode, rather than a HPR. A single-center, retrospective, observational study was carried out over 10 years in Taiwan. A total of 124 patients with at least one peritonitis episode were the study subjects. The Cox proportional hazard model was used to assess the impact of HPR on clinical outcomes. Multivariate logistic regression was conducted to determine the independent factors associated with a HPR. In the multivariate Cox regression model, HPR was still a significant predictor for technique failure, patient mortality and dropout from peritoneal dialysis (PD). Factors independently associated with a HPR were peritonitis occurrence during the first year after the start of CAPD and the first peritonitis infected with streptococcus species. Peritonitis during the first year after PD commencement and the first peritonitis infected by streptococcus species were significantly associated with an increased risk of a HPR. Our data also indicate that HPR was correlated with technique failure, patient mortality and dropout from PD, thus highlighting the need and role of future studies to reduce this complication.